CONSORT 2010 changes and testing blindness in RCTs

The Lancet

Volumn 375, Issue 9721, 2010, Pages 1144-1146

  Schulz, Kenneth F ^a   Altman, Douglas G ^b   Moher, David ^c,d   Fergusson, Dean ^c,d  

^a FAMILY HEALTH INTERNATIONAL   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; MEDICAL LITERATURE; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THEORY-PRACTICE RELATIONSHIP;

EID: 77950187973     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)60413-8     Document Type: Note

References (16)

1. Schulz K.F., Altman D.G., Moher D., and for the CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ 340 (2010) c332
2. Moher D., Schulz K.F., and Altman D.G. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 357 (2001) 1191-1194
3. Kolahi J., Bang H., and Park J. Towards a proposal for assessment of blinding success in clinical trials: up-to-date review. Community Dent Oral Epidemiol 37 (2009) 477-484
4. Wood L., Egger M., Gluud L.L., et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ 336 (2008) 601-605
5. Schulz K.F., Chalmers I., Hayes R.J., and Altman D.G. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 273 (1995) 408-412
6. Schulz K.F., Chalmers I., and Altman D.G. The landscape and lexicon of blinding in randomized trials. Ann Intern Med 136 (2002) 254-259
7. Fergusson D., Glass K.C., Waring D., and Shapiro S. Turning a blind eye: the success of blinding reported in a random sample of randomised, placebo controlled trials. BMJ 328 (2004) 432
8. Sackett D.L. Commentary: Measuring the success of blinding in RCTs: don't, must, can't or needn't?. Int J Epidemiol 36 (2007) 664-665
9. Day S.J., and Altman D.G. Statistics notes: blinding in clinical trials and other studies. BMJ 321 (2000) 504
10. Altman D.G., Schulz K.F., and Moher D. Turning a blind eye: testing the success of blinding and the CONSORT statement. BMJ 328 (2004) 1135
11. Schulz K.F., and Grimes D.A. The Lancet handbook of essential concepts in clinical research (2006), Elsevier, Edinburgh
12. Senn S.J. Turning a blind eye: authors have blinkered view of blinding. BMJ 328 (2004) 1135-1136
13. Sackett D.L. Turning a blind eye: why we don't test for blindness at the end of our trials. BMJ 328 (2004) 1136
14. Schulz K.F., and Grimes D.A. Blinding in randomised trials: hiding who got what. Lancet 359 (2002) 696-700
15. Vitiello B., Davies M., Arnold L.E., et al. Assessment of the integrity of study blindness in a pediatric clinical trial of risperidone. J Clin Psychopharmacol 25 (2005) 565-569
16. Quitkin F.M., Rabkin J.G., Gerald J., Davis J.M., and Klein D.F. Validity of clinical trials of antidepressants. Am J Psychiatry 157 (2000) 327-337